CL2008002829A1 - Combinacion farmaceutica de dosis oral fija que comprende aliskireno y valsartan; uso de la combinacion para tratar hipertension, angina, infarto al miocardio, arterioscleosis, nefropatia diabetica, insuficiencia renal, entre otras; metodos de preparacion de la combinacion en forma de bicapa y en forma se tableta sobre encapsulada. - Google Patents

Combinacion farmaceutica de dosis oral fija que comprende aliskireno y valsartan; uso de la combinacion para tratar hipertension, angina, infarto al miocardio, arterioscleosis, nefropatia diabetica, insuficiencia renal, entre otras; metodos de preparacion de la combinacion en forma de bicapa y en forma se tableta sobre encapsulada.

Info

Publication number
CL2008002829A1
CL2008002829A1 CL2008002829A CL2008002829A CL2008002829A1 CL 2008002829 A1 CL2008002829 A1 CL 2008002829A1 CL 2008002829 A CL2008002829 A CL 2008002829A CL 2008002829 A CL2008002829 A CL 2008002829A CL 2008002829 A1 CL2008002829 A1 CL 2008002829A1
Authority
CL
Chile
Prior art keywords
combination
aliskiren
valsartan
arterioscleosis
angina
Prior art date
Application number
CL2008002829A
Other languages
English (en)
Spanish (es)
Inventor
Ralf Altenburger
Nicole Bargenda
Michaela Anna Maria Bock
Sabine Adler
Bruno Buss
Stefan Hirsch
Saun Babiole
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40377183&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008002829(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2008002829A1 publication Critical patent/CL2008002829A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2008002829A 2007-09-28 2008-09-24 Combinacion farmaceutica de dosis oral fija que comprende aliskireno y valsartan; uso de la combinacion para tratar hipertension, angina, infarto al miocardio, arterioscleosis, nefropatia diabetica, insuficiencia renal, entre otras; metodos de preparacion de la combinacion en forma de bicapa y en forma se tableta sobre encapsulada. CL2008002829A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US97592507P 2007-09-28 2007-09-28
US97591907P 2007-09-28 2007-09-28
US97590107P 2007-09-28 2007-09-28
US97590907P 2007-09-28 2007-09-28

Publications (1)

Publication Number Publication Date
CL2008002829A1 true CL2008002829A1 (es) 2009-06-26

Family

ID=40377183

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008002829A CL2008002829A1 (es) 2007-09-28 2008-09-24 Combinacion farmaceutica de dosis oral fija que comprende aliskireno y valsartan; uso de la combinacion para tratar hipertension, angina, infarto al miocardio, arterioscleosis, nefropatia diabetica, insuficiencia renal, entre otras; metodos de preparacion de la combinacion en forma de bicapa y en forma se tableta sobre encapsulada.

Country Status (18)

Country Link
US (1) US20100209480A1 (enExample)
EP (1) EP2205233A2 (enExample)
JP (1) JP2010540547A (enExample)
KR (1) KR20100063090A (enExample)
CN (1) CN101808631A (enExample)
AR (1) AR066168A1 (enExample)
AU (1) AU2008309058B2 (enExample)
BR (1) BRPI0817442A2 (enExample)
CA (1) CA2698330A1 (enExample)
CL (1) CL2008002829A1 (enExample)
CO (1) CO6270217A2 (enExample)
EC (1) ECSP10010052A (enExample)
MA (1) MA31706B1 (enExample)
MX (1) MX2010003441A (enExample)
PE (1) PE20090654A1 (enExample)
TN (1) TN2010000135A1 (enExample)
TW (1) TW200924737A (enExample)
WO (1) WO2009045795A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2483718C2 (ru) * 2007-09-28 2013-06-10 Новартис Аг Галеновые композиции алискирена
AR073651A1 (es) * 2008-09-24 2010-11-24 Novartis Ag Formulaciones galenicas de compuestos organicos
CN102361633A (zh) * 2009-03-20 2012-02-22 诺瓦提斯公司 包含阿利吉仑的药物组合物
CN102348452A (zh) * 2009-03-20 2012-02-08 诺瓦提斯公司 缬沙坦和阿利吉仑的固定剂量组合的盖仑制剂
WO2011116115A1 (en) * 2010-03-16 2011-09-22 Novartis Ag Aliskiren composition comprising a medium chain fatty acid, their process of manufacturing
TR201002256A1 (tr) * 2010-03-24 2011-10-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Stabil aliskiren formülasyonları
CN101926793B (zh) * 2010-08-05 2012-08-15 成都自豪药业有限公司 一种含替米沙坦和阿利吉伦的联合用药物及其制备方法
IN2014CN02610A (enExample) * 2011-10-12 2015-08-07 Dow Global Technologies Llc
BR112014015620A8 (pt) * 2011-12-26 2017-07-04 Novartis Ag comprimidos e agentes revestidos a seco
CN103349652B (zh) * 2013-05-11 2014-11-19 辽宁大学 含有四氢萘酰胺化合物或其可药用盐的高药物载荷片剂
JP2023553010A (ja) 2020-12-03 2023-12-20 バテル・メモリアル・インスティテュート 非ウイルス性送達のためのポリマーナノ粒子およびｄｎａナノ構造組成物ならびに方法
CA3216359A1 (en) 2021-04-07 2022-10-13 Battelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
WO2025122954A1 (en) 2023-12-08 2025-06-12 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
MY144477A (en) * 2004-03-17 2011-09-30 Novartis Ag Galenic formulations of organic compounds
PT1799199E (pt) * 2004-10-08 2012-07-03 Novartis Ag Uso de inibidores da renina para a prevenção ou tratamento da disfunção diastólica ou insuficiência cardíaca diastólica
MY146830A (en) * 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
AU2006241219A1 (en) * 2005-04-27 2006-11-02 Novartis Ag Methods of treating atherosclerosis

Also Published As

Publication number Publication date
TN2010000135A1 (en) 2011-09-26
WO2009045795A2 (en) 2009-04-09
CN101808631A (zh) 2010-08-18
MA31706B1 (fr) 2010-09-01
ECSP10010052A (es) 2010-04-30
CO6270217A2 (es) 2011-04-20
MX2010003441A (es) 2010-04-21
PE20090654A1 (es) 2009-06-27
AU2008309058A1 (en) 2009-04-09
KR20100063090A (ko) 2010-06-10
CA2698330A1 (en) 2009-04-09
EP2205233A2 (en) 2010-07-14
AR066168A1 (es) 2009-07-29
WO2009045795A3 (en) 2009-07-16
AU2008309058B2 (en) 2012-08-09
BRPI0817442A2 (pt) 2015-06-16
JP2010540547A (ja) 2010-12-24
TW200924737A (en) 2009-06-16
US20100209480A1 (en) 2010-08-19

Similar Documents

Publication Publication Date Title
CL2008002829A1 (es) Combinacion farmaceutica de dosis oral fija que comprende aliskireno y valsartan; uso de la combinacion para tratar hipertension, angina, infarto al miocardio, arterioscleosis, nefropatia diabetica, insuficiencia renal, entre otras; metodos de preparacion de la combinacion en forma de bicapa y en forma se tableta sobre encapsulada.
CL2008003298A1 (es) Forma de dosificacion oral solida que comprende a) un compuesto de accion doble en concentracion entre 4 y 90%, b) un excipiente farmaceuticamente aceptable; proceso de preparación; uso en el tratamiento de enfermedades cardiovasculares y/o renales.
ECSP10010693A (es) Compuestos pirazólicos 436
CL2007001870A1 (es) Composicion farmaceutica de dosificacion solida que comprende valsartan, amlodipina, hidroclorotiazida y aditivos farmaceuticamente aceptables; procedimiento de preparacion; y uso para el tratamiento de hipertension, insuficiencia cardiaca, infarto d
ECSP088188A (es) Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
UY32461A (es) Sal de tosilato de 6-metil-5-(metil-1h-pirazol-5-il)-n-{[e-(metilsulfonil)piridin-2-il]metil -2-oxo-1-[3-(trifluorometil)fenil]-1,2-dihidropiridin-3-carboxamida
CL2011000170A1 (es) Composicion farmaceutica solida y estabilizada que comprende un ingrediente farmaceuticamente activo, oxido de titanio y un plastificante; procedimiento para estabilizar la composicion farmaceutica durante una irradiacion luminosa.
CL2009001766A1 (es) Composicion farmaceutica solida para administracion oral que comprende: un taxano sustancialmente amorfo definido, un portador hidrofilico definido y un tensoactivo definido; metodo para preparar la composicion; y su uso para tratar una enfermedad neoplasica.
ECSP13012423A (es) FORMA DE DOSIFICACION FARMACEUTICA QUE COMPRENDE 6'-FLUORO-(N-METIL- O N,N-DIMETIL)-4-FENIL-4',9'-DIHIDRO-3'H-ESPIRO[CICLOHEXAN-1,1'-PIRANO[3,4,b]INDOL]-4-AMINA PARA EL TRATAMIENTO DE DOLOR NEUROPATICO
CR11232A (es) Compuestos de tiazolopirina modulares de sirtuina
CL2011000935A1 (es) Composicion farmaceutica que comprende acetaminofeno y un material de tramadol complejo, que exhibe una liberacion sostenida y coordinada a traves de una capa de liberacion sostenida y otra de liberacion inmediata; metodo de preparacion;y el uso de un material complejo de tramadol y acetaminofeno para preparar un medicamento para el tratamiento del dolor.
CR11749A (es) Tratamiento de la disnea asociada con insuficiencia cardiaca aguda con relaxina
MX392330B (es) Uso farmacéutico de una esfingomielinasa ácida (asm) con aumento escalonado de la dosis para tratar la deficiencia de esfingomielinasa ácida.
CL2011003371A1 (es) Composicion farmaceutica de dosis fija, oral, solida y estable que comprende irbesartan, besilato de amlodipino y excipientes; procedimientos de preparacion; uso en el tratamiento de la hipertension.
HN2006014095A (es) Forma cristalina ortorrombica del maleato de asenapina
UY31788A (es) Formulación farmacéutica sólida con liberación retardada
ATE505203T1 (de) Pharmazeutische kombination aus aliskiren und valsartan
UY31839A (es) Compuestos
AR066924A1 (es) Formulacion de nevirapina de liberacion prolongada
UY31758A (es) Forma cristalina anhidra de maleato de orvepitant
UY31768A (es) Uso de dronedarona o una sal aceptable farmacéuticamente de ésta, para la preparación de un medicamento para regular el nivel de potasio en la sangre
AR062784A1 (es) Tratmiento de los vertigos con acetil -l- leucina
AR054595A1 (es) Formulaciones/composiciones farmaceuticas de guanfacina apropiadas para forma de administracion diaria en una unica dosis
SV2010003773A (es) 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos